These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura. Zheng XL J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215 [TBL] [Abstract][Full Text] [Related]
3. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13. Plaimauer B; Schiviz A; Kaufmann S; Höllriegl W; Rottensteiner H; Scheiflinger F J Thromb Haemost; 2015 Nov; 13(11):2053-62. PubMed ID: 26340698 [TBL] [Abstract][Full Text] [Related]
4. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. Thomas MR; de Groot R; Scully MA; Crawley JT EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702 [TBL] [Abstract][Full Text] [Related]
5. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. Shelat SG; Smith P; Ai J; Zheng XL J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212 [TBL] [Abstract][Full Text] [Related]
6. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Gerritsen HE; Turecek PL; Schwarz HP; Lämmle B; Furlan M Thromb Haemost; 1999 Nov; 82(5):1386-9. PubMed ID: 10595623 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. Cruz MA; Whitelock J; Dong JF Thromb Haemost; 2003 Dec; 90(6):1204-9. PubMed ID: 14652658 [TBL] [Abstract][Full Text] [Related]
8. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Kremer Hovinga JA; Studt JD; Lämmle B Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):417-21. PubMed ID: 15692254 [TBL] [Abstract][Full Text] [Related]
9. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Scheiflinger F; Knöbl P; Trattner B; Plaimauer B; Mohr G; Dockal M; Dorner F; Rieger M Blood; 2003 Nov; 102(9):3241-3. PubMed ID: 12855569 [TBL] [Abstract][Full Text] [Related]
10. [Determination of the ADAMTS13 antigen and its activity in TTP patients and carriers]. Liu F; Feys HB; Dong NZ; Bai X; Vanhoorelbeke K; Deckmyn H; Ruan CG Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):154-7. PubMed ID: 16792913 [TBL] [Abstract][Full Text] [Related]
12. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883 [TBL] [Abstract][Full Text] [Related]
13. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. Jin M; Cataland S; Bissell M; Wu HM J Thromb Haemost; 2006 Feb; 4(2):333-8. PubMed ID: 16420561 [TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Peyvandi F; Ferrari S; Lavoretano S; Canciani MT; Mannucci PM Br J Haematol; 2004 Nov; 127(4):433-9. PubMed ID: 15521921 [TBL] [Abstract][Full Text] [Related]
15. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura]. Matsumoto M Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429 [TBL] [Abstract][Full Text] [Related]